tiprankstipranks
Trending News
More News >
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
US Market
Advertisement

Inhibikase Therapeutics (IKT) Ownership - Who Owns Inhibikase Therapeutics?

Compare
166 Followers

Inhibikase Therapeutics (IKT) Ownership Overview

9.80%4.43%60.31%5.96%19.50%
60.31% Other Institutional Investors
5.96% ETFs
19.50% Public Companies and
Individual Investors
The ownership structure of Inhibikase Therapeutics (IKT) stock is a mix of institutional, retail, and individual investors. Approximately 70.70% of the company’s stock is owned by Institutional Investors, 9.80% is owned by Insiders, and 19.50% is owned by Public Companies and Individual Investors.
The ownership structure of Inhibikase Therapeutics (IKT) stock is a mix of institutional, retail, and individual investors. Approximately 64.74% of the company’s stock is owned by Institutional Investors, 9.80% is owned by Insiders, and 5.96% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Oct 23, 2024
xxxxxxxxxxxxx
$500050
Oct 23, 2024
xxxxxxxxxxxxx
$2000200
Oct 23, 2024
xxxxxxxxxxxxx
$198650

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Jun 30, 2025
xxxxxxxxxxxxx
$5144638
Jun 30, 2025
xxxxxxxxxxxxx
$10592971

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
6,125,000Institution8.22%10,412,500
5,432,293Institution7.29%9,234,898
5,335,433Insider7.16%9,070,236
2,901,352Institution3.89%4,932,298
2,760,750Institution3.70%4,693,275
2,638,276Institution3.54%4,485,069
1,494,586Institution2.01%2,540,796
1,460,000Insider1.96%2,482,000
365,000Insider0.49%620,500
273,614Institution0.37%465,144

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
2,760,750Institution3.70%4,693,275
273,614Institution0.37%465,144
144,170Institution0.19%245,089
44,358Institution0.06%75,409
40,000Institution0.05%68,000
33,537Institution0.05%57,013
4,230Institution<0.01%7,191

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
2,228,292Institution2.99%3,520,701
818,336Institution1.10%1,391,171
479,036Institution0.64%823,942
343,146Institution0.46%542,171
290,814Institution0.39%459,486
140,324Institution0.19%241,357
64,135Institution0.09%109,030
35,752Institution0.05%56,488
30,183Institution0.04%52,820
5,276Institution<0.01%9,074

FAQ

Who Owns Inhibikase Therapeutics (IKT)?
According to the latest TipRanks data, approximately 60.31% of the company's stock is held by institutional investors, 9.80% is held by insiders, and 19.50% is held by retail investors.
    What percentage of Inhibikase Therapeutics (IKT) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 60.31% of Inhibikase Therapeutics (IKT) stock is held by institutional investors.
      What percentage of Inhibikase Therapeutics (IKT) stock is held by retail investors?
      According to the latest TipRanks data, approximately 19.50% of Inhibikase Therapeutics (IKT) stock is held by retail investors.
        Who owns the most shares of Inhibikase Therapeutics (IKT)?
        Peter Harwin owns the most shares of Inhibikase Therapeutics (IKT).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis